Testing a New Score to Predict Survival in Pancreatic Cancer Patients
Checks whether a new score can predict survival in people with localized pancreatic cancer.
Plain-language title generated from the registry record
Registry title: The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer
Key facts
- Where
- Vienna, AustriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT05752812, who can take part
Where in Austria
- Department of General Surgery, Division of Visceral Surgery, Medical University of ViennaVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Vienna
- Trial code
- NCT05752812
- Record updated
- 27 October 2023
- Original description
The goal of this observational study is to validate a pretreatment prognostic score (Heidelberg Prognostic Pancreatic Cancer Score - HELPP) in patients with pancreatic ductal adenocarcinoma.Read full original descriptionShow less
The HELPP Score: A Pretreatment Prognostic Score to Predict Survival and Patterns of Recurrence in Localized Non-Metastatic Pancreatic Cancer - a Multicenter Prospective Validation Study
The goal of this observational study is to validate a pretreatment prognostic score (Heidelberg Prognostic Pancreatic Cancer Score - HELPP) in patients with pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* Is the HELPP score able to predict median overall survival in a prospective multi-institutional cohort of patients with pretherapeutic localized non-metastatic pancreatic cancer? * Is the HELPP score able to predict median recurrence-free survival and patterns of recurrence after resection of pancreatic cancer?
Inclusion: ≥18 years old; fit to undergo elective pancreatic resection or palliative therapy; localized non-metastatic pancreatic ductal adenocarcinoma; informed consent provided.
Exclusion: patients receiving surgery for peripancreatic cancer; missing mandatory pretreatment laboratory values; patients with a diagnosis other than pancreatic ductal adenocarcinoma on histopathology; missing informed consent; missing mandatory pretreatment clinicopathologic data; incomplete follow-up records; follow-up < 24 months; pregnancy.